Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
Kimberly Ha notes that many big pharma companies are partnering with academic institutions and that oncology, followed by neurology is one of the hottest areas in acquisitions
Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.
OneMedRadio interviewed Thomas Braun, CEO of Verisante Technologies [CVE:VRS], a medical device company committed to commercializing innovative systems for the early detection of cancer.
Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.